Voices
Paolo Tarantino: What Is the Value of Intercepting Molecular Resistance in HR+/HER2- Breast Cancer?
Paolo Tarantino/X, Jason A. Mouabbi/X and Hope Rugo/ucsfhealth.org

Paolo Tarantino: What Is the Value of Intercepting Molecular Resistance in HR+/HER2- Breast Cancer?

Paolo Tarantino, Vivian Saykaly Visiting Professor in Medical Oncology at McGill University Health Centre, shared a post by The Breast Friends Podcast on X, adding:

“What is the value of intercepting molecular resistance in HR+/HER2- metastatic breast cancer?

Here, our podcast episode dissecting the SERENA6 strategy with the one and only Hope Rugo.
Listen for free. And don’t forget to follow.”

Quoting The Breast Friends Podcast:

“Episode 5 of The Breast Friends Podcast is out now, featuring special guest Dr. Hope Rugo.

Watch now on YouTube.

Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music.”

You can also read:

SERENA-6: Switching to Camizestrant at ESR1 Mutation Emergence Extends First-Line Benefit in HR+/HER2− Advanced Breast CancerPaolo Tarantino: What Is the Value of Intercepting Molecular Resistance in HR+/HER2- Breast Cancer?

Breast Cancer cancer Hope Rugo OncoDaily Oncology Paolo Tarantino SERENA-6 The Breast Friends Podcast